The lung cancer cure rate is dismal and has. The Effect of Tumor Size on Curability of Stage I Non-small Cell Lung Cancers*
|
|
- Morris Harper
- 6 years ago
- Views:
Transcription
1 The Effect of Tumor Size on Curability of Stage I Non-small Cell Lung Cancers* Juan P. Wisnivesky, MD, MPH; David Yankelevitz, MD; and Claudia I. Henschke, PhD, MD, FCCP Objective: The objective of this study was to determine the relationship between tumor size and curability of stage I non-small cell lung cancer. Methods: From the Surveillance, Epidemiology, and End Results registry 2003, we identified all primary non-small cell lung cancer cases that were diagnosed prior to autopsy. Among these cases, we narrowed the focus to those diagnosed in 1988 or later, and to 7,620 patients who had undergone curative surgical resection. Kaplan-Meier survival curves were obtained for these stage I malignancies for five tumor size categories (ie, 5 to 15 mm, 16 to 25 mm, 26 to 35 mm, 36 to 45 mm, and > 45 mm). The 12-year Kaplan-Meier estimator of survival was used as a measure of lung cancer cure rate. Results: Among 7,620 stage I cancers, cure rates decreased with increasing tumor size. The 12-year survival rates for patients with tumors 5 to 15 mm in diameter was 69% (95% confidence interval [CI], 64 to 74%), 63% for those with tumors 16 to 25 mm in diameter (95% CI, 60 to 67%), 58% for those with tumors 26 to 35 mm in diameter (95% CI, 54 to 61%), 53% for those with tumors 36 to 45 mm in diameter (95% CI, 48 to 57%), and 43% for those with tumors > 45 mm in diameter (95% CI, 39 to 48%). Cure rates were statistically significantly different for all tumor size categories (p < 0.05) except for the groups with tumors 26 to 35 mm and 36 to 45 mm in diameter (p 0.10). Conclusions: Smaller tumor size at diagnosis is associated with improved curability within stage I non-small cell lung cancers. These results suggest that further subclassification by size within stage I may be important. (CHEST 2004; 126: ) Key words: curability; non-small cell lung cancer; stage I; survival Abbreviations: CI confidence interval; SEER Surveillance, Epidemiology, and End Results The lung cancer cure rate is dismal and has remained essentially unchanged over the past 3 decades. 1 The stage of disease at diagnosis represents one of the most powerful determinants of outcome in patients with non-small cell lung cancer, with patients having earlier stage disease having a better chance of long-term survival. 2 Unfortunately, *From the Division of General Internal Medicine and Pulmonary, Critical Care, and Sleep Medicine (Dr. Wisnivesky), Mount Sinai School of Medicine, and the Department of Radiology (Drs. Yanelevitz and Henschke), New York-Presbyterian Hospital- Weill Cornell Medical Center, New York, NY. Manuscript received December 16, 2003; revision accepted April 21, Reproduction of this article is prohibited without written permission from the American College of Chest Physicians ( permissions@chestnet.org). Correspondence to: Juan P. Wisnivesky, MD, MPH, Department of Medicine, Mount Sinai School of Medicine, One Gustave L. LevyPlace,Box1087,NewYork,NY10029; juan.wisnivesky@ mssm.edu only small proportions of non-small cell lung cancer cases are diagnosed at an earlier stage. The importance of tumor size on the survival of patients with early non-small cell lung cancers was recognized in the 1997 American Joint Committee on Cancer staging system, 2 as stage I was subdivided into stage IA (tumors 3 cm in diameter) and stage IB (tumors 3 cm in diameter). However, controversy remains concerning the relationships between tumor size and prognosis, and the appropriate cutoff size at which to stratify patients within stage I. 3 Although some studies 4,5 have shown better survival for patients with stage I tumors measuring 2cm, or even 1 cm, others have not. 3,6 Smaller tumor size at the time of diagnosis was found to be associated with an improved 5-year survival rate in some of these studies. However, the 5-year survival rate of patients with smaller tumors may be higher as a consequence of lead time even if early diagnosis does not increase the chance of cure. 7 Thus, the relation- CHEST / 126 / 3/ SEPTEMBER,
2 ship of tumor size and curability cannot be inferred from the results of these studies. This study was conducted to better determine the effect of tumor size on the curability of stage I cancers. Materials and Methods The Surveillance, Epidemiology, and End Results (SEER) program is a National Cancer Institute-funded database that has been collecting clinicopathologic data on all incident cancer cases in selected geographic areas of the United States since From the SEER 9 registry 2003, we identified all cases of non-small cell lung cancer (tumor site codes, 34.0 to 34.9; International Classification of Diseases for Oncology-2 morphology codes, 8010 to 8040, 8050 to 8076, 8140, 8143, 8250 to 8260, 8310, 8320, 8323, 8470 to 8490, and 8550 to 8573) that were diagnosed prior to autopsy. 8 Among these cases, we narrowed the focus to those diagnosed in 1988 or later, as the histologic classification had changed. There were 143,796 such cases. Among these 143,796 cases, we identified cases of primary stage I cancer using the American Joint Committee on Cancer criteria, 2 as follows: T1, noninvasive tumor with a diameter of 3 cm, without evidence of invasion more proximal than the lobar bronchus (SEER tumor extent code 10); T2, tumor with any of the following features among 3 cm in dimension, involvement of main bronchus 2 cm distal to the carina, invasion of the visceral pleura, association with atelectasis or obstructive pneumonitis that extends to the hilar region but does not involve the entire lung (SEER tumor extent codes 20 and 40); N0, absence of lymph node metastasis (SEER lymph node code 0); and M0, no distant metastasis (SEER tumor extension 40). We found 11,142 cases of T1N0M0 or T2N0M0 cancer. Among these stage I cases, 7,620 patients underwent resection (ie, lobectomy at least; site-specific surgery codes 30 to 70). Histology was identified according to the World Health Organization definition published in Tumor size, as defined by its greatest diameter, was based on those recorded in the pathology report. Cases were classified into the following five tumor size (ie, diameter) categories: 5 to 15 mm; 16 to 25 mm; 26 to 35 mm; 36 to 45 mm; and 45 mm. We observed a round-off pattern with respect to the reporting of tumor size in the SEER database. Thus, size categories were defined so that tumors that were clustered together due to this phenomenon would be placed in the same group. We constructed lung-cancer specific survival curves separately by tumor size category using the Kaplan-Meier method, which adjusted for deaths from all other causes. 10 The cause of death provided in the SEER registry is abstracted from the National Center for Health Statistics database of consolidated death certificates from the vital statistics office in each state. As previously defined by Buell, 11 the cure rate can be determined by the point at which the cumulative survival no longer changes, that is, when the slope of the survival curve approaches zero. Based on this definition, we used the 12-year cumulative lung cancer survival rate as a measure of the cure rate, given that the slope of the survival curves for all tumor size categories approached zero before this time point. Differences in 12-year survival rates were evaluated using a z-test based on the large sample distribution of the Kaplan-Meier estimators. 12 The analyses were performed using a statistical software package (SAS; SAS Institute; Cary, NC). Results Of the 7,620 patients with stage I non-small cell lung cancer, 3,273 (43%) were female. The mean ( SD) age was 66 9 years. The histologic classification of the tumors showed that there were 2,611 cases of squamous cell carcinoma (34%), 3,319 cases of adenocarcinoma (44%), and 516 cases of large cell carcinoma (7%). Among the 7,620 cases, we found 786 (10%) to be 5 to 15 mm in diameter, 2,290 (30%) to be 16 to 25 mm in diameter, 2,006 (26%) to be 26 to 35 mm in diameter, 1,100 (15%) to be 36 to 45 mm in diameter, and 1,438 (19%) to be 45 mm in diameter. The Kaplan-Meier survival curves stratified by tumor size category are shown in Figure 1. Among these 7,620 stage I cancers, cure rates decreased with increasing tumor size. The lung cancer cure rates were as follows: tumors 5 to 15 mm in diameter, 69% (95% confidence interval [CI], 64 to 74%); tumors 16 to 25 mm in diameter, 63% (95% CI, 60 to 67%); tumors 26 to 35 mm in diameter, 58% (95% CI, 54 to 61%); tumors 36 to 45 mm in diameter, 53% (95% CI, 48 to 57%); and tumors 45 mm in diameter, 43% (95% CI, 39 to 48%) [Table 1]. A comparison of cure rates according to tumor size category showed that rates were statistically significantly different for all categories (p 0.05), except for tumor sizes 26 to 35 mm and 36 to 45 mm (p 0.10). Discussion While differences in survival between patients with tumors 3cmand 3 cm in diameter have been determined in prior studies, a similar relationship for lesions of different sizes within stage I, particularly tumors 3 cm in diameter, has not been established. The results of this study show that smaller tumor size at diagnosis is associated with improved curability for patients with stage I nonsmall cell lung cancers. Disease-specific cure rates for lung cancer ranged from as high as 69% (95% CI, 64 to 74%) for malignancies 5 to 15 mm in diameter to approximately 43% (95% CI, 39 to 48%) for those 45 mm in diameter. The observed association between smaller tumor size and improved survival can be explained by several possible mechanisms. First, if a lung cancer is diagnosed when it is small instead of when it is large, then survival, which is measured from the time of diagnosis, should be increased by the lead time from earlier diagnosis. 7 However, as shown in Figure 1, the slope of the survival curves for all tumor size categories approached zero, suggesting that by 12 years after diagnosis even the smallest tumors that 762 Clinical Investigations
3 Figure 1. Cure rates according to tumor size category were statistically significantly different for all categories (p 0.05) except for groups of patients with tumor diameters of 26 to 35 mm and 36 to 45 mm (p 0.10). Table 1 Cure Rates for Non-small Cell Lung Cancers According to Tumor Size Tumor Size, mm Patients, No. (%) Cure Rate, % (95% CI) (10) 69 (64 74) ,290 (30) 63 (60 67) ,006 (26) 58 (54 61) ,100 (15) 53 (48 57) 45 1,438 (19) 43 (39 48) had metastasized before resection had sufficient time to progress and cause the death of the individual. The survival curves for all tumor sizes become almost parallel beyond this time point, suggesting that differences in cumulative survival represent true differences in long-term outcomes. Thus, the 12- year survival rate, our measure of curability, should have not been subject to lead-time bias. Second, it has been suggested that the smaller the tumor size at detection the greater the probability that the lesion is a case of overdiagnosis. These overdiagnosed lesions are defined as tumors that, although pathologically classified as cancer, would not result in the death of the person. 13,14 Because overdiagnosed cases will effectively dilute lung cancer cases with healthy individuals, it can artificially increase the observed survival of the smaller tumors. We have previously shown using the same cancer registry that the casefatality rate of untreated stage I lung cancer appears to be of the order of 90% even when the tumor diameter is 15 mm. 15 Thus, our finding of improved curability with smaller tumor size is unlikely to be explained by the possibility of overdiagnosis. The most probable interpretation of our results is that earlier treatment increases the probability of curing malignant and potentially fatal lung cancer. The prognostic value of tumor size within stage I has been evaluated in several studies. 3,4,16 21 In a study including 286 stage I tumors, Watanabe et al 16 showed significant differences in 5-year survival rates for patients with tumors 3cm,3to5cm,and 5 cm in diameter. Similarly, Carbone et al 17 showed that patients with stage I cancers 5 cm in diameter had a significantly poorer prognosis and proposed to change the classification of these lesions. Additionally, several studies have shown that there is important variation in the 5-year survival rates of stage IA subgroups. Recently, Gajra et al 4 found in a series of 246 stage IA cases that patients with tumors 1.5 cm in diameter had an improved outcome compare to those with tumors 1.5 cm in size. Koike et al 5 found a significant difference in survival between patients with non-small cell lung cancers 2cmin diameter and those with lung cancers 2cmin diameter, but tumor size was not a significant prognostic factor on multivariate analysis. Similarly, Ishida et al, 19 Read et al, 18 Riquet et al, 20 and Padilla et al 21 found significant differences in 5-year survival rates between patients with tumors 2 cm in diameter and those with tumors measuring 2.1 to 3 cm. Harpole et al 22 compared the 5-year survival rates of groups with tumor sizes of 2cm,2to4cm,and 4 cm. There were significant differences between CHEST / 126 / 3/ SEPTEMBER,
4 each group. However, as some of these studies utilized 5-year survival rates as the measure of prognosis and used the log rank test or Cox regression to compare different tumor size categories, their results may have been confounded by lead-time bias. Conversely, other studies have found no difference in the survival of stage I lung cancer patients according to tumor size. Yanagi et al 6 found no significant difference in survival between patients with lesions 2 cm in diameter and those with lesions 2 cm in diameter among 64 cases of non-small cell lung cancer. Similarly, Patz et al, 3 using a Cox proportional hazard model, found no survival difference according to tumor size among 510 patients with pathologic stage IA non-small cell lung cancers, of which only a minority (approximately 10%) were 1 cm in diameter. Thus, the study may not have had sufficient power to detect meaningful differences in survival. 23 Our results suggest that further subclassification by tumor size within stage I may be important, as already has been done in the present TNM classification of the tumors of oral cavity, pharynx, thyroid gland, and breast. 24 Based on the growing evidence that tumor size is a key prognostic indicator of lung cancer survival, accurate imaging and pathologic measurements should be obtained in patients with these malignancies. Ideally, the length, width, and height of the tumor should be measured according to a standardized, well-defined measurement approach. Some studies using low-dose CT scan screening showed that low-dose CT scanning is substantially more sensitive than a chest radiograph for the detection of early lung cancer. The majority of the lung cancers detected with CT scanning in these studies were of the earliest stage (ie, stage IA) and typically were 10 mm in diameter, a marked contrast to the distribution of lung cancers detected in clinical practice. For lung cancer screening to be effective, however, the ability of CT scans to detect smaller lesions has to translate into a decrease in lung cancer deaths or an increase in its complement, the cure rate. The results of this study suggest that early detection increases the curability of clinically diagnosed lung cancer. Applying these results to cases detected by screening, however, requires consideration of other issues. First, this study was limited to surgically resected stage I cases. In a screening program, some patients may refuse or be ineligible for surgery, and, thus, the tumor sizespecific cure rates for screening-detected cases may be lower than those estimated in the study. Conversely, because, overall, tumors in screeningdetected cases will tend to be smaller (mostly 10 mm) and the patients will be asymptomatic, the opposite phenomenon may be observed. Second, to evaluate the effectiveness of screening, the effect of competing causes of death on the overall survival rate needs to be taken into consideration. Information regarding the cause of death for patients in the SEER registry is abstracted from death certificates. Although the death certificate is an important source of data on disease incidence, prevalence, and mortality, inaccuracies in the reported cause of death in this document have been described. 31,32 However, our estimates of lung cancer survival rates using the SEER database are similar to those reported in other studies using hospital-based cases series. 2 Moreover, the large number of patients with stage I lung cancer in SEER database allow for a precise estimation of cure rate in these patients. In summary, tumor size at diagnosis among patients with stage I lung cancer is associated with the probability of cure. These results suggests that further subclassification by size within stage I may be important. References 1 Smith RA, Glynn TJ. Epidemiology of lung cancer. Radiol Clin North Am 2000; 38: Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997; 111: Patz EF Jr, Rossi S, Harpole DH Jr, et al. Correlation of tumor size and survival in patients with stage IA non-small cell lung cancer. Chest 2000; 117: Gajra A, Newman N, Gamble GP, et al. Impact of tumor size on survival in stage IA non-small cell lung cancer: a case for subdividing stage IA disease. Lung Cancer 2003; 42: Koike T, Terashima M, Takizawa T, et al. Clinical analysis of small-sized peripheral lung cancer. J Thorac Cardiovasc Surg 1998; 115: Yanagi S, Sugiura H, Morikawa T, et al. Tumor size does not have prognostic significance in stage Ia NSCLC. Anticancer Res 2000; 20: Morrison A, Screening. Rothman KJ, et al, eds. Modern epidemiology. Philadelphia, PA: Lippincott-Raven, Ries LAG, Eisner MP, Kosary CL, et al, eds. SEER Cancer Statistics Review, ; Bethesda, MD: National Cancer Institute. Available at /. Accessed August 11, Percy C VHV, Muir C, eds. International classification of diseases for oncology. 2nd ed. Geneva, Switzerland: World Health Organization, Kaplan EL, Meier P. Nonparametric estimation for incomplete obserbations. J Am Stat Assoc 1958; 53: Buell PE. The importance of tumor size in prognosis for resected bronchogenic carcinoma. J Surg Oncol 1971; 3: Klein J, Moeschberger ML. Survival analysis: techniques for censored and truncated data. New York, NY: Springer-Verlag, Bailar JC III. Screening for lung cancer: where are we now? Am Rev Respir Dis 1984; 130: Black WC, Welch HG. Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy. N Engl J Med 1993; 328: Clinical Investigations
5 15 Henschke CI, Wisnivesky JP, Yankelevitz DF, et al. Small stage I cancers of the lung: genuineness and curability. Lung Cancer 2003; 39: Watanabe Y, Shimizu J, Oda M, et al. Proposals regarding some deficiencies in the new international staging system for non-small cell lung cancer. Jpn J Clin Oncol 1991; 21: Carbone E, Asamura H, Takei H, et al. T2 tumors larger than five centimeters in diameter can be upgraded to T3 in non-small cell lung cancer. J Thorac Cardiovasc Surg 2001; 122: Read RC, Yoder G, Schaeffer RC. Survival after conservative resection for T1 N0 M0 non-small cell lung cancer. Ann Thorac Surg 1990; 49: Ishida T, Yano T, Maeda K, et al. Strategy for lymphadenectomy in lung cancer three centimeters or less in diameter. Ann Thorac Surg 1990; 50: Riquet M, Manac h D, Le Pimpec Barthes F, et al. Prognostic value of T and N in non small cell lung cancer three centimeters or less in diameter. Eur J Cardiothorac Surg 1997; 11: Padilla J, Calvo V, Penalver JC, et al. Surgical results and prognostic factors in early non-small cell lung cancer. Ann Thorac Surg 1997; 63: Harpole DH Jr, Herndon JE II, Young WG Jr, et al. Stage I nonsmall cell lung cancer: a multivariate analysis of treatment methods and patterns of recurrence. Cancer 1995; 76: Black WC. Unexpected observations on tumor size and survival in stage IA non-small cell lung cancer. Chest 2000; 117: Watanabe Y. Substaging of stage I: a commentary. Lung Cancer 2003; 42: Henschke CI, McCauley DI, Yankelevitz DF, et al. Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet 1999; 354: Henschke CI, Naidich DP, Yankelevitz DF, et al. Early lung cancer action project: initial findings on repeat screenings. Cancer 2001; 92: Swensen SJ. CT screening for lung cancer. AJR Am J Roentgenol 2002; 179: Diederich S, Wormanns D, Semik M, et al. Screening for early lung cancer with low-dose spiral CT: prevalence in 817 asymptomatic smokers. Radiology 2002; 222: Sone S, Li F, Yang ZG, et al. Results of three-year mass screening programme for lung cancer using mobile low-dose spiral computed tomography scanner. Br J Cancer 2001; 84: Sobue T, Moriyama N, Kaneko M, et al. Screening for lung cancer with low-dose helical computed tomography: anti-lung cancer association project. J Clin Oncol 2002; 20: Smith Sehdev AE, Hutchins GM. Problems with proper completion and accuracy of the cause-of-death statement. Arch Intern Med 2001; 161: Kircher T, Nelson J, Burdo H. The autopsy as a measure of accuracy of the death certificate. N Engl J Med 1985; 313: CHEST / 126 / 3/ SEPTEMBER,
Ethnic Disparities in the Treatment of Stage I Non-small Cell Lung Cancer. Juan P. Wisnivesky, MD, MPH, Thomas McGinn, MD, MPH, Claudia Henschke, PhD,
Ethnic Disparities in the Treatment of Stage I Non-small Cell Lung Cancer Juan P. Wisnivesky, MD, MPH, Thomas McGinn, MD, MPH, Claudia Henschke, PhD, MD, Paul Hebert, PhD, Michael C. Iannuzzi, MD, and
More informationVisceral pleural involvement (VPI) of lung cancer has
Visceral Pleural Involvement in Nonsmall Cell Lung Cancer: Prognostic Significance Toshihiro Osaki, MD, PhD, Akira Nagashima, MD, PhD, Takashi Yoshimatsu, MD, PhD, Sosuke Yamada, MD, and Kosei Yasumoto,
More informationPrognostic value of visceral pleura invasion in non-small cell lung cancer q
European Journal of Cardio-thoracic Surgery 23 (2003) 865 869 www.elsevier.com/locate/ejcts Prognostic value of visceral pleura invasion in non-small cell lung cancer q Jeong-Han Kang, Kil Dong Kim, Kyung
More informationLung cancer is a major cause of cancer deaths worldwide.
ORIGINAL ARTICLE Prognostic Factors in 3315 Completely Resected Cases of Clinical Stage I Non-small Cell Lung Cancer in Japan Teruaki Koike, MD,* Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, Yasunori Sohara,
More informationKey words: diameter; lung cancer; lung carcinoma; non-small cell lung cancer; size; staging; T stage; TNM
Diameter of Non-small Cell Lung Cancer Correlates With Long-term Survival* Implications for T Stage Carlos M. Mery, MD, MPH; Anastasia N. Pappas, MSW, MPH; Bryan M. Burt, MD; Raphael Bueno, MD, FCCP; Philip
More informationLung cancer pleural invasion was recognized as a poor prognostic
Visceral pleural invasion classification in non small cell lung cancer: A proposal on the basis of outcome assessment Kimihiro Shimizu, MD a Junji Yoshida, MD a Kanji Nagai, MD a Mitsuyo Nishimura, MD
More informationLYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG
LYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Takehiro Watanabe, MD a Yuzo Kurita, MD b Akira Yokoyama, MD b Keiichi
More informationLung cancer is a prevalent health problem worldwide. It is the leading cause
Prognostic factors in resected stage I non small cell lung cancer with a diameter of 3 cm or less: Visceral pleural invasion did not influence overall and disease-free survival Jung-Jyh Hung, MD, a,b Chien-Ying
More informationSuperior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis
ORIGINAL ARTICLES: Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis Shun-ichi Watanabe, MD, Kenji Suzuki, MD, and Hisao Asamura, MD
More informationIn 1989, Deslauriers et al. 1 described intrapulmonary metastasis
ORIGINAL ARTICLE Prognosis of Resected Non-Small Cell Lung Cancer Patients with Intrapulmonary Metastases Kanji Nagai, MD,* Yasunori Sohara, MD, Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, and Etsuo Miyaoka,
More informationExtent of visceral pleural invasion and the prognosis of surgically resected node-negative non-small cell lung cancer
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Extent of visceral pleural invasion and the prognosis of surgically resected node-negative non-small cell lung cancer Yangki Seok 1, Ji Yun Jeong 2 & Eungbae
More informationImpact of Large Tumor Size on Survival After Resection of Pathologically Node Negative (pn0) Non Small Cell Lung Cancer
Impact of Large Tumor Size on Survival After Resection of Pathologically Node Negative (pn0) Non Small Cell Lung Cancer Shin-ichi Takeda, MD, Shimao Fukai, MD, Hikotaro Komatsu, MD, Etsuo Nemoto, MD, Kenji
More informationPrognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai, China
www.springerlink.com Chin J Cancer Res 23(4):265 270, 2011 265 Original Article Prognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai,
More informationAlthough the international TNM classification system
Prognostic Significance of Perioperative Serum Carcinoembryonic Antigen in Non-Small Cell Lung Cancer: Analysis of 1,000 Consecutive Resections for Clinical Stage I Disease Morihito Okada, MD, PhD, Wataru
More informationVisceral pleura invasion (VPI) was adopted as a specific
ORIGINAL ARTICLE Visceral Pleura Invasion Impact on Non-small Cell Lung Cancer Patient Survival Its Implications for the Forthcoming TNM Staging Based on a Large-Scale Nation-Wide Database Junji Yoshida,
More informationVisceral Pleural Invasion Is Not Predictive of Survival in Patients With Lung Cancer and Smaller Tumor Size
GENERAL THORACIC Visceral Pleural Invasion Is Not Predictive of Survival in Patients With Lung Cancer and Smaller Tumor Size Elizabeth David, MD, Peter F. Thall, PhD, Neda Kalhor, MD, Wayne L. Hofstetter,
More informationTemporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008
Special Report Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Matthew B. Schabath, PhD, Zachary J. Thompson, PhD,
More informationNode-Negative Non-small Cell Lung Cancer
ORIGINAL ARTICLE Node-Negative Non-small Cell Lung Cancer Pathological Staging and Survival in 1765 Consecutive Cases Benjamin M. Robinson, BSc, MBBS, Catherine Kennedy, RMRA, Jocelyn McLean, RN, MN, and
More informationThe right middle lobe is the smallest lobe in the lung, and
ORIGINAL ARTICLE The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao, MD, PhD,* Sakae Okumura, MD,* Mun Mingyon,
More informationWith recent advances in diagnostic imaging technologies,
ORIGINAL ARTICLE Management of Ground-Glass Opacity Lesions Detected in Patients with Otherwise Operable Non-small Cell Lung Cancer Hong Kwan Kim, MD,* Yong Soo Choi, MD,* Kwhanmien Kim, MD,* Young Mog
More informationPulmonary resection remains the most effective. Survival in Synchronous vs Single Lung Cancer. Upstaging Better Reflects Prognosis
Survival in Synchronous vs Single Lung Cancer Upstaging Better Reflects Prognosis Marcel Th. M. van Rens, MD; Pieter Zanen, MD, PhD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD;
More informationStage IB Nonsmall Cell Lung Cancers: Are They All the Same?
ORIGINAL ARTICLES: GENERAL THORACIC GENERAL THORACIC SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article,
More informationMarcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD; and Jules M. M. van den Bosch, MD, PhD, FCCP
Prognostic Assessment of 2,361 Patients Who Underwent Pulmonary Resection for Non-small Cell Lung Cancer, Stage I, II, and IIIA* Marcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans
More informationSlide 1. Slide 2. Slide 3. Investigation and management of lung cancer Robert Rintoul. Epidemiology. Risk factors/aetiology
Slide 1 Investigation and management of lung cancer Robert Rintoul Department of Thoracic Oncology Papworth Hospital Slide 2 Epidemiology Second most common cancer in the UK (after breast). 38 000 new
More informationPrognostic Significance of the Extent of Visceral Pleural Invasion in Completely Resected Node-Negative Non-small Cell Lung Cancer
CHEST Original Research Prognostic Significance of the Extent of Visceral Pleural Invasion in Completely Resected Node-Negative Non-small Cell Lung Cancer Jung-Jyh Hung, MD, PhD ; Wen-Juei Jeng, MD ; Wen-Hu
More informationHistory of Limited Resection for Non-small Cell Lung Cancer
Review History of Limited Resection for n-small Cell Lung Cancer Haruhiko Nakamura, MD, PhD, 1 Sugishita Kazuyuki, MD, 1 rihito Kawasaki, MD, 1 Masahiko Taguchi, MD, PhD, 1 and Harubumi Kato, MD, PhD 2
More informationORIGINAL PAPER. Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery
Nagoya J. Med. Sci. 79. 37 ~ 42, 2017 doi:10.18999/nagjms.79.1.37 ORIGINAL PAPER Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery Naoki Ozeki, Koji
More informationLung Cancer Risk Associated With New Solid Nodules in the National Lung Screening Trial
Cardiopulmonary Imaging Original Research Pinsky et al. Lung Cancer Risk Associated With New Nodules Cardiopulmonary Imaging Original Research Paul F. Pinsky 1 David S. Gierada 2 P. Hrudaya Nath 3 Reginald
More informationThe accurate assessment of lymph node involvement is
ORIGINAL ARTICLE Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage Classification? Shenhai Wei, MD, PhD,*
More informationProjected Outcomes Using Different Nodule Sizes to Define a Positive CT Lung Cancer Screening Examination
DOI:10.1093/jnci/dju284 First published online October 20, 2014 The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
More informationPrognostic value of visceral pleural invasion in resected non small cell lung cancer diagnosed by using a jet stream of saline solution
Maruyama et al General Thoracic Surgery Prognostic value of visceral pleural invasion in resected non small cell lung cancer diagnosed by using a jet stream of saline solution Riichiroh Maruyama, MD Fumihiro
More informationIntraoperative pleural lavage cytology after lung resection as an independent prognostic factor for staging lung cancer
Intraoperative pleural lavage cytology after lung resection as an independent prognostic factor for staging lung cancer Yasushi Shintani, MD, hd, a Mitsunori Ohta, MD, hd, a Teruo Iwasaki, MD, hd, a Naoki
More informationValidation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer
Original Article Validation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer Hee Suk Jung 1, Jin Gu Lee 2, Chang Young Lee 2, Dae Joon Kim 2, Kyung Young Chung 2 1 Department
More informationIn non small cell lung cancer, metastasis to lymph nodes, the N factor, is
Okada et al General Thoracic Surgery Border between N1 and N2 stations in lung carcinoma: Lessons from lymph node metastatic patterns of lower lobe tumors Morihito Okada, MD, PhD Toshihiko Sakamoto, MD,
More informationLung cancer is one of the most common and most. Delays in the Diagnosis and Treatment of Lung Cancer*
Delays in the Diagnosis and Treatment of Lung Cancer* Eija-Riitta Salomaa, MD, PhD; Susanna Sällinen, BM; Heikki Hiekkanen, MSc; and Kari Liippo, MD, PhD Study objectives: This study was undertaken to
More informationThe projection of short- and long-term survival for. Conditional Survival Among Patients With Carcinoma of the Lung*
Conditional Survival Among Patients With Carcinoma of the Lung* Ray M. Merrill, PhD, MPH; Donald Earl Henson, MD; and Michael Barnes, PhD Objective: One- and 5-year probabilities of survival or death change
More informationSince the introduction of low-dose helical computed tomography
Original Article Prognostic Impact of Tumor Size Eliminating the Ground Glass Opacity Component Modified Clinical T Descriptors of the Tumor, Node, Metastasis Classification of Lung Cancer Shota Nakamura,
More informationBone Metastases in Muscle-Invasive Bladder Cancer
Journal of the Egyptian Nat. Cancer Inst., Vol. 18, No. 3, September: 03-08, 006 AZZA N. TAHER, M.D.* and MAGDY H. KOTB, M.D.** The Departments of Radiation Oncology* and Nuclear Medicine**, National Cancer
More informationIn the mid 1970s, visceral pleural invasion (VPI) was included
ORIGINAL ARTICLE Tumor Invasion of Extralobar Soft Tissue Beyond the Hilar Region Does Not Affect the Prognosis of Surgically Resected Lung Cancer Patients Hajime Otsuka, MD,* Genichiro Ishii, MD, PhD,*
More informationChapter 13 Cancer of the Female Breast
Lynn A. Gloeckler Ries and Milton P. Eisner INTRODUCTION This study presents survival analyses for female breast cancer based on 302,763 adult cases from the Surveillance, Epidemiology, and End Results
More informationClinical significance of skipping mediastinal lymph node metastasis in N2 non-small cell lung cancer
Original Article Clinical significance of skipping mediastinal lymph node metastasis in N2 non-small cell lung cancer Jun Zhao*, Jiagen Li*, Ning Li, Shugeng Gao Department of Thoracic Surgery, National
More informationState of the art in surgery for early stage NSCLC does the number of resected lymph nodes matter?
Review Article State of the art in surgery for early stage NSCLC does the number of resected lymph nodes matter? Laura Romero Vielva 1, Manuel Wong Jaen 1, José A. Maestre Alcácer 2, Mecedes Canela Cardona
More informationMEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I PERIPHERAL NON-SMALL-CELL LUNG CANCER
MEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I PERIPHERAL NON-SMALL-CELL LUNG CANCER Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Hideki Akamatsu, MD a Yuzo
More informationThe 8th Edition Lung Cancer Stage Classification
The 8th Edition Lung Cancer Stage Classification Elwyn Cabebe, M.D. Medical Oncology, Hematology, and Hospice and Palliative Care Valley Medical Oncology Consultants Director of Quality, Medical Oncology
More informationLung cancer screening: panacea or pipe dream?
Annals of Oncology 16 (Supplement 2): ii215 ii219, 2005 doi:10.1093/annonc/mdi723 Lung cancer screening: panacea or pipe dream? A. K. Ganti 1 & J. L. Mulshine 2 1 Division of Hematology-Oncology, Department
More informationEarly Lung Cancer Action Project: A Summary of the Findings on Baseline Screening
Early Lung Cancer Action Project: A Summary of the Findings on Baseline Screening CLAUDIA I. HENSCHKE, a DOROTHY I. MCCAULEY, b DAVID F. YANKELEVITZ, a DAVID P. NAIDICH, b GEORGEANN MCGUINNESS, b OLLI
More informationThe prognostic significance of central fibrosis of adenocarcinoma
Prognostic Significance of the Size of Central Fibrosis in Peripheral Adenocarcinoma of the Lung Kenji Suzuki, MD, Tomoyuki Yokose, MD, Junji Yoshida, MD, Mitsuyo Nishimura, MD, Kenro Takahashi, MD, Kanji
More informationThe Spectrum of Management of Pulmonary Ground Glass Nodules
The Spectrum of Management of Pulmonary Ground Glass Nodules Stanley S Siegelman CT Society 10/26/2011 No financial disclosures. Noguchi M et al. Cancer 75: 2844-2852, 1995. 236 surgically resected peripheral
More informationThe Prognostic Value of Ratio-Based Lymph Node Staging in Resected Non Small-Cell Lung Cancer
Original Article The Prognostic Value of Ratio-Based Lymph Node Staging in Resected Non Small-Cell Lung Cancer Chen Qiu, MD,* Wei Dong, MD,* Benhua Su, MBBS, Qi Liu, MD,* and Jiajun Du, PhD Introduction:
More informationRisk Factors for Occult Mediastinal Metastases in Clinical Stage I Non-Small Cell Lung Cancer
ORIGINAL ARTICLES: SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article, you must have either an STS
More informationValue of Systematic Mediastinal Lymph Node Dissection During Pulmonary Metastasectomy
Value of Systematic Mediastinal Lymph Node Dissection During Pulmonary Metastasectomy Florian Loehe, MD, Sonja Kobinger, MD, Rudolf A. Hatz, MD, Thomas Helmberger, MD, Udo Loehrs, MD, and Heinrich Fuerst,
More informationMaster Class: Fundamentals of Lung Cancer
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationEvaluation of the new TNM staging system proposed by the International Association for the Study of Lung Cancer at a single institution
Evaluation of the new TNM staging system proposed by the International Association for the Study of Lung Cancer at a single institution Kotaro Kameyama, MD, a Mamoru Takahashi, MD, a Keiji Ohata, MD, a
More informationSurgical resection is the first treatment of choice for
Predictors of Lymph Node and Intrapulmonary Metastasis in Clinical Stage IA Non Small Cell Lung Carcinoma Kenji Suzuki, MD, Kanji Nagai, MD, Junji Yoshida, MD, Mitsuyo Nishimura, MD, and Yutaka Nishiwaki,
More informationVisceral Pleura Invasion by Non-Small Cell Lung Cancer: An Underrated Bad Prognostic Factor
Visceral Pleura Invasion by Non-Small Cell Lung Cancer: An Underrated Bad Prognostic Factor Dominique Manac h, MD, Marc Riquet, MD, PhD, Jacques Medioni, MD, Françoise Le Pimpec-Barthes, MD, Antoine Dujon,
More informationAlthough ipsilateral intrapulmonary metastasis (PM), Evaluation of TMN Classification for Lung Carcinoma With Ipsilateral Intrapulmonary Metastasis
Evaluation of TMN Classification for Lung Carcinoma With Ipsilateral Intrapulmonary Metastasis Morihito Okada, MD, Noriaki Tsubota, MD, Masahiro Yoshimura, MD, Yoshifumi Miyamoto, MD, and Reiko Nakai,
More informationRevisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis
Jpn J Clin Oncol 1997;27(5)305 309 Revisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis -, -, - - 1 Chest Department and 2 Section of Thoracic Surgery,
More informationBronchogenic Carcinoma
A 55-year-old construction worker has smoked 2 packs of ciggarettes daily for the past 25 years. He notes swelling in his upper extremity & face, along with dilated veins in this region. What is the most
More informationCarcinoma of the Lung
THE ANNALS OF THORACIC SURGERY Journal of The Society of Thoracic Surgeons and the Southern Thoracic Surgical Association VOLUME 1 I - NUMBER 3 0 MARCH 1971 Carcinoma of the Lung M. L. Dillon, M.D., and
More informationPET CT for Staging Lung Cancer
PET CT for Staging Lung Cancer Rohit Kochhar Consultant Radiologist Disclosures Neither I nor my immediate family members have financial relationships with commercial organizations that may have a direct
More informationSurgery remains the mainstay treatment for localized
Surgical Results in T2N0M0 Nonsmall Cell Lung Cancer Patients With Large Tumors 5 cm or Greater in Diameter: What Regulates Outcome? Yasuhiko Ohta, MD, Ryuichi Waseda, MD, Hiroshi Minato, MD, Naoki Endo,
More informationPeritoneal Involvement in Stage II Colon Cancer
Anatomic Pathology / PERITONEAL INVOLVEMENT IN STAGE II COLON CANCER Peritoneal Involvement in Stage II Colon Cancer A.M. Lennon, MB, MRCPI, H.E. Mulcahy, MD, MRCPI, J.M.P. Hyland, MCh, FRCS, FRCSI, C.
More informationAfter primary tumor treatment, 30% of patients with malignant
ESTS METASTASECTOMY SUPPLEMENT Alberto Oliaro, MD, Pier L. Filosso, MD, Maria C. Bruna, MD, Claudio Mossetti, MD, and Enrico Ruffini, MD Abstract: After primary tumor treatment, 30% of patients with malignant
More informationOriginal Article Clinical predictors of lymph node metastasis in lung adenocarcinoma: an exploratory study
Int J Clin Exp Med 2016;9(5):8765-8769 www.ijcem.com /ISSN:1940-5901/IJCEM0017315 Original Article Clinical predictors of lymph node metastasis in lung adenocarcinoma: an exploratory study Zhijun Zhu,
More informationSublobar Resection Provides an Equivalent Survival After Lobectomy in Elderly Patients With Early Lung Cancer
Sublobar Resection Provides an Equivalent Survival After Lobectomy in Elderly Patients With Early Lung Cancer Jiro Okami, MD, PhD, Yuri Ito, PhD, Masahiko Higashiyama, MD, PhD, Tomio Nakayama, MD, PhD,
More informationIndeterminate Pulmonary Nodules in Patients with Colorectal Cancer
Indeterminate Pulmonary Nodules in Patients with Colorectal Cancer Jai Sule 1, Kah Wai Cheong 2, Stella Bee 2, Bettina Lieske 2,3 1 Dept of Cardiothoracic and Vascular Surgery, University Surgical Cluster,
More informationPredictive risk factors for lymph node metastasis in patients with small size non-small cell lung cancer
Original Article Predictive risk factors for lymph node metastasis in patients with small size non-small cell lung cancer Feichao Bao, Ping Yuan, Xiaoshuai Yuan, Xiayi Lv, Zhitian Wang, Jian Hu Department
More informationReport to Waikato Medical Research Foundation
Report to Waikato Medical Research Foundation Understanding the importance of tumour biology and socio-demographic difference in cancer stage at diagnosis using the Midland Lung Cancer Register Ross Lawrenson
More informationLung cancer is still the leading cause of cancer mortality in
ORIGINAL ARTICLE Postoperative Prognosis in Patients with Non-small Cell Lung Cancer According to the Method of Initial Detection Takeshi Hanagiri, MD, PhD, Kenji Sugio, MD, PhD, Makiko Mizukami, MD, PhD,
More informationPrognostic factors in curatively resected pathological stage I lung adenocarcinoma
Original Article Prognostic factors in curatively resected pathological stage I lung adenocarcinoma Yikun Yang 1, Yousheng Mao 1, Lin Yang 2, Jie He 1, Shugeng Gao 1, Juwei Mu 1, Qi Xue 1, Dali Wang 1,
More informationManagement of Multiple Pure Ground-Glass Opacity Lesions in Patients with Bronchioloalveolar Carcinoma
ORIGINAL ARTICLE Management of Multiple Pure Ground-Glass Opacity Lesions in Patients with Bronchioloalveolar Carcinoma Hong Kwan Kim, MD,* Yong Soo Choi, MD,* Jhingook Kim, MD, PhD,* Young Mog Shim, MD,
More informationRatio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer
Original Article Ratio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer Fangfang Chen 1 *, Yanwen Yao 2 *, Chunyan
More informationLung cancer is the most common cause of cancer-related
Original Article Prognostic Factors Based on Clinicopathological Data Among the Patients with Resected Peripheral Squamous Cell Carcinomas of the Lung Tomonari Kinoshita, MD,* Takashi Ohtsuka, MD, PhD,*
More informationRelevance of an extensive follow-up after surgery for nonsmall cell lung cancer
ORIGINAL ARTICLE LUNG CANCER Relevance of an extensive follow-up after surgery for nonsmall cell lung cancer Delphine Gourcerol 1,2, Arnaud Scherpereel 1,2, Stephane Debeugny 3, Henri Porte 2,4, Alexis
More informationSmall Pulmonary Nodules: Our Preliminary Experience in Volumetric Analysis of Doubling Times
Small Pulmonary Nodules: Our Preliminary Experience in Volumetric Analysis of Doubling Times Andrea Borghesi, MD Davide Farina, MD Roberto Maroldi, MD Department of Radiology University of Brescia Brescia,
More informationMediastinal Staging. Samer Kanaan, M.D.
Mediastinal Staging Samer Kanaan, M.D. Overview Importance of accurate nodal staging Accuracy of radiographic staging Mediastinoscopy EUS EBUS Staging TNM Definitions T Stage Size of the Primary Tumor
More informationSurgical Management of Metastatic Colon Cancer: analysis of the Surveillance, Epidemiology and End Results (SEER) database
Surgical Management of Metastatic Colon Cancer: analysis of the Surveillance, Epidemiology and End Results (SEER) database Hadi Khan, MD 1, Adam J. Olszewski, MD 2 and Ponnandai S. Somasundar, MD 1 1 Department
More informationThe Impact of Adjuvant Chemotherapy in Pulmonary Large Cell Neuroendocrine Carcinoma (LCNC)
The Impact of Adjuvant Chemotherapy in Pulmonary Large Cell Neuroendocrine Carcinoma (LCNC) Disclosure None Background Torino, Italy LCNC Rare tumor (2% to 3% all resected primary lung cancers) Preoperative
More informationXiang Hu*, Liang Cao*, Yi Yu. Introduction
Original Article Prognostic prediction in gastric cancer patients without serosal invasion: comparative study between UICC 7 th edition and JCGS 13 th edition N-classification systems Xiang Hu*, Liang
More informationMolly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010
LSU HEALTH SCIENCES CENTER NSCLC Guidelines Feist-Weiller Cancer Center Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 Initial Evaluation/Intervention: 1. Pathology Review 2. History and Physical
More informationTHE BENEFITS OF BIG DATA
THE BENEFITS OF BIG DATA Disclosures I am a named inventor on a number of patents and patent applications relating to the evaluation of pulmonary nodules on CT scans of the chest which are owned by Cornell
More informationPrognostic Factors for the Survival of Patients with Esophageal Carcinoma in the U.S.
1434 Prognostic Factors for the Survival of Patients with Esophageal Carcinoma in the U.S. The Importance of Tumor Length and Lymph Node Status Mohamad A. Eloubeidi, M.D., M.H.S. 1,2 Renee Desmond, Ph.D.
More informationAccepted Manuscript. Risk stratification for distant recurrence of resected early stage NSCLC is under construction. Michael Lanuti, MD
Accepted Manuscript Risk stratification for distant recurrence of resected early stage NSCLC is under construction Michael Lanuti, MD PII: S0022-5223(17)32392-9 DOI: 10.1016/j.jtcvs.2017.10.063 Reference:
More informationVisceral pleural invasion (VPI) of lung cancer has been
ORIGINAL ARTICLE Visceral Pleural Invasion Classification in Non Small- Cell Lung Cancer in the 7th Edition of the Tumor, Node, Metastasis Classification for Lung Cancer: Validation Analysis Based on a
More informationThe Significance of One-Station N2 Disease in the Prognosis of Patients With Nonsmall-Cell Lung Cancer
ORIGINAL ARTICLES: SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article, you must have either an STS
More informationLung Cancer Staging: The Revised TNM Classification
Norwegian Society of Thoracic Imaging Oslo, October 2011 Lung Cancer Staging: The Revised TNM Classification Sujal R Desai King s College Hospital, London Lung Cancer The Scale of the Problem Leading cause
More informationThe roles of adjuvant chemotherapy and thoracic irradiation
Factors Predicting Patterns of Recurrence After Resection of N1 Non-Small Cell Lung Carcinoma Timothy E. Sawyer, MD, James A. Bonner, MD, Perry M. Gould, MD, Robert L. Foote, MD, Claude Deschamps, MD,
More informationSmall solid noncalcified pulmonary nodules detected by screening chest computed tomography
Respiratory Medicine (2007) 101, 1880 1884 Small solid noncalcified pulmonary nodules detected by screening chest computed tomography Sang-Man Jin a,b, Seung-Ho Choi c, Chul-Gyu Yoo a,b, Young-Whan Kim
More informationSurveillance following treatment of primary ocular melanoma
Surveillance following treatment of primary ocular melanoma Introduction 50% of UM patients relapse with predominantly liver metastases Risk of metastatic disease can be predicted relatively accurately
More informationThe tumor, node, metastasis (TNM) staging system of lung
ORIGINAL ARTICLE Peripheral Direct Adjacent Lobe Invasion Non-small Cell Lung Cancer Has a Similar Survival to That of Parietal Pleural Invasion T3 Disease Hao-Xian Yang, MD, PhD,* Xue Hou, MD, Peng Lin,
More informationLong-Term Outcome and Late Recurrence in Patients with Completely Resected Stage IA Non-small Cell Lung Cancer
ORIGINAL ARTICLE Long-Term Outcome and Late Recurrence in Patients with Completely Resected Stage IA Non-small Cell Lung Cancer Ryo Maeda, MD,* Junji Yoshida, MD,* Genichiro Ishii, MD, Keiju Aokage, MD,*
More informationComplete surgical excision remains the greatest potential
ORIGINAL ARTICLE Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD,* Charles E. Eastridge, MD, Elizabeth A. Tolley,
More informationUtility of 18 F-FDG PET/CT in metabolic response assessment after CyberKnife radiosurgery for early stage non-small cell lung cancer
Utility of F-FDG PET/CT in metabolic response assessment after CyberKnife radiosurgery for early stage non-small cell lung cancer Ngoc Ha Le 1*, Hong Son Mai 1, Van Nguyen Le 2, Quang Bieu Bui 2 1 Department
More informationPrognostic impact of intratumoral vascular invasion in non-small cell lung cancer patients
1 Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan 2 Department of Pathology, Research Center for Innovative Oncology, National Cancer Center Hospital East,
More informationLUNG CANCER PATHOLOGY: UPDATE ON NEUROENDOCRINE LUNG TUMORS
LUNG CANCER PATHOLOGY: UPDATE ON NEUROENDOCRINE LUNG TUMORS William D. Travis, M.D. Attending Thoracic Pathologist Memorial Sloan Kettering Cancer Center New York, NY PULMONARY NE TUMORS CLASSIFICATION
More informationThyroid Cancer: When to Treat? MEGAN R. HAYMART, MD
Thyroid Cancer: When to Treat? MEGAN R. HAYMART, MD ASSOCIATE PROFESSOR OF MEDICINE UNIVERSITY OF MICHIGAN MICHIGAN AACE 2018 ANNUAL MEETING Thyroid Cancer: When Not to Treat? FOCUS WILL BE ON LOW-RISK
More informationLymph node dissection for lung cancer is both an old
LOBE-SPECIFIC EXTENT OF SYSTEMATIC LYMPH NODE DISSECTION FOR NON SMALL CELL LUNG CARCINOMAS ACCORDING TO A RETROSPECTIVE STUDY OF METASTASIS AND PROGNOSIS Hisao Asamura, MD Haruhiko Nakayama, MD Haruhiko
More informationThe effect of surgeon volume on procedure selection in non-small cell lung cancer surgeries. Dr. Christian Finley MD MPH FRCSC McMaster University
The effect of surgeon volume on procedure selection in non-small cell lung cancer surgeries Dr. Christian Finley MD MPH FRCSC McMaster University Disclosures I have no conflict of interest disclosures
More informationRadiological staging of lung cancer. Shukri Loutfi,MD,FRCR Consultant Thoracic Radiologist KAMC-Riyadh
Radiological staging of lung cancer Shukri Loutfi,MD,FRCR Consultant Thoracic Radiologist KAMC-Riyadh Bronchogenic Carcinoma Accounts for 14% of new cancer diagnoses in 2012. Estimated to kill ~150,000
More informationLung cancer is the leading cause of cancer deaths worldwide.
ORIGINAL ARTICLE Predictors of Death, Local Recurrence, and Distant Metastasis in Completely Resected Pathological Stage-I Non Small-Cell Lung Cancer Jung-Jyh Hung, MD, PhD,* Wen-Juei Jeng, MD, Wen-Hu
More information